Abstract: A fidaxomicin purification method, comprising: fermenting Actinoplanes sp. HS-16-20 to generate fermented liquid; conducting solid/liquid separation on the fermented liquid, soaking mycelium in an organic solvent, and filtering to obtain a solution containing fidaxomicin; treating the solution with nanofiltration concentrate, and separating to obtain fidaxomicin crude product; conducting preparative column chromatography on the fidaxomicin crude product, eluting with an acid aqueous solution containing an organic solvent, and separating to obtain the refined fidaxomicin product.

Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.

Abstract: The present invention relates to the field of pharmaceuticals, especially to the field of veterinary drugs, and more particularly to a crystal form of milbemycin A3 oxime, able to be characterized by the X-ray powder diffraction spectrogram, infrared absorption (IR) spectrogram, differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA), etc. Furthermore, the present invention also relates to a method for preparing the crystal form of milbemycin A3 oxime and to a use of the crystal form of milbemycin A3 oxime as an insecticidal and acaricidal agent.

Abstract: Provided are a Streptomyces (Streptomyces hygroscopicus) HS7523 and a method for preparing milbemycin A3 by culturing the Streptomyces. The Streptomyces (Streptomyces hygroscopicus) HS7523 is deposited in “China General Microbiological Culture Collection Center” with an accession number of CGMCC No. 9672 on Sep. 16, 2014.

Abstract: The present invention relates to a disaccharide intermediate and a synthesis method thereof, relates to the chemical pharmaceutical field, and more specifically relates to a method for preparing a disaccharide segment of a key intermediate for chemically synthesizing heparin and heparinoid compounds. Disclosed are a new disaccharide intermediate and three methods for synthesizing the disaccharide intermediate, that is, compounds of a formula (4) and glucopyranose protected by different anomeric carbon are made to react in the presence of an active agent, to obtain the disaccharide intermediate. According to the technical solutions of the present invention, synthetic raw materials are easy to obtain, have a mild reaction condition, and are suitable for industrialized production.

Abstract: Disclosed are a method for preparing a benzodioxole derivative (AD-35) shown by Formula (I) and an intermediate thereof. The method of the present invention involves: using piperic acid as a raw material; and performing bromination, esterification, cyanidation, cyclopropane lactamization, amide nitrogen alkylation, deprotection, piperidine nitrogen alkylation and salification to obtain the compound of Formula (I). The method has cheap and easily available start raw materials, short synthesis routes and simple operation, and is suitable for industrial production.

Abstract: An indole derivative as expressed by Formula (I), a preparation method thereof, a pharmaceutical salt, and use thereof as a therapeutic agent, especially as a FGFR inhibitor. Each substituent in Formula (I) has identical definition as specified in the specification.

Abstract: Provided are a Streptomyces (Streptomyces hygroscopicus) HS7522 and a method for preparing milbemycin A4 by culturing the Streptomyces. The Streptomyces (Streptomyces hygroscopicus) HS7522 of the present invention is deposited in “China General Microbiological Culture Collection Center” with an accession number of CGMCC No. 9671 on Sep. 16, 2014.

Abstract: The present invention provides adiabatic plug flow reactors suitable for the production of chlorinated and/or fluorinated propene and higher alkenes from the reaction of chlorinated and/or fluorinated alkanes and chlorinated and/or fluorinated alkenes. The reactors comprise one or more designs that minimize the production of by-products at a desired conversion.

Abstract: An AC/DC conversion apparatus includes first, second, and third AC/DC conversion modules operated by a controller in two modes of operation. In the first mode, the input AC signal is 3-phase and each of the three modules are enabled to handle a respective one of the input phases. In the second mode, the input AC signal is single phase and the first and second modules are enabled to deliver output power based on the single-phase AC input, while the controller actuates an H-bridge switches in the third module to which active filter circuitry is connected, to reduce an AC component in the output signal. The active filter circuitry can be selectively connected to the H-bridge switches when single-phase operation is desired, which circuitry may be disposed in a filter housing having male electrical terminals that cooperate with corresponding female terminals associated with the third module.

Abstract: Intermediate compounds for the preparation of Praziquantel are provided. In particular, the intermediate compounds provided include a compound of formula (IV) and a compound of formula (V). Also provided are processes for preparing the intermediate compounds. Additionally, the raw materials are inexpensive and easy to obtain, the key intermediates are easy to prepare, and the total reaction yield and purity of the obtained target compound Praziquantel is high, so that industrialized mass production of Praziquantel using the intermediate compounds is easy to achieve.

Abstract: The present invention relates to an acrylic acid derivative as shown in general formula (I), a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, the preparation method thereof, a pharmaceutical composition containing same, and the use thereof as therapeutic agents, in particular as selective estrogen receptor degraders (SERD), wherein the substituents of general formula (I) are the same as those defined in the description.

Abstract: An apparatus includes a controller, a switching block, and a three-phase bidirectional AC/DC converter. The switching block has a first interface connected to a power grid, a second interface connected to an electric motor, and a third interface connected to the three-phase bidirectional AC/DC converter that includes first, second, and third single-phase AC/DC conversion modules, and which have inputs and outputs joined at an output node, and a respective transformer configured to provide electrical isolation. In a first mode of operation, the switching block connects the power grid to the AC/DC converter for charging a battery connected to the output node and disconnects the electric motor. In a second mode of operation, the switching block disconnects the power grid and connects the electric motor to the AC/DC converter which is controlled to convert DC power drawn from the battery to energize the electric motor.

Abstract: The present invention relates to a mixer, an apparatus comprising the mixer and a reactor, and processes incorporating the same. The mixer comprises an inlet (104) to a chamber (102), wherein the chamber inlet angle is less than 90°. The mixer further comprises an expander zone (106) that expands outwardly at an expander angle of less than 90°. The mixer may be coupled to a reactor at its outlet, which may closely approximate the size of the reactor inlet due to the expander (106).

Abstract: Disclosed is a preparation method for praziquantel and intermediates thereof. The method includes: obtaining a target product praziquantel by using ?-phenethylamine as an initial raw material through a condensation reaction with chloroacetyl chloride, a substitution reaction with ethanolamine, and an acylation reaction with cyclohexanecarbonyl chloride, followed by an oxidation reaction and cyclization reaction. Also disclosed are two key intermediates, namely, a compound of formula IV and a compound of formula V for preparing praziquantel. The preparation method is reasonable and simple in its technological design, uses moderate reaction conditions, and is economical and environmentally friendly. Additionally, the raw materials are inexpensive and easy to obtain, the key intermediates are easy to prepare, and the total reaction yield and purity of the obtained target compound praziquantel is high, so that industrialized mass production is easy to achieve.

Abstract: A sixteen-membered macrolide compound and use thereof, the compound structure being represented in formula (I), wherein R is CH3 or C2H5. The present compound has a wide range of application in the preparation of chemicals for preventing and controlling insect pests and mites of agriculture and forestry.

Abstract: An indole derivative as expressed by Formula (I), a preparation method thereof, a pharmaceutical salt, and use thereof as a therapeutic agent, especially as a FGFR inhibitor. Each substituent in Formula (I) has identical definition as specified in the specification.

Abstract: A fidaxomicin purification method, comprising: fermenting Actinoplanes sp. HS-16-20 to generate fermented liquid; conducting solid/liquid separation on the fermented liquid, soaking mycelium in an organic solvent, and filtering to obtain a solution containing fidaxomicin; treating the solution with nanofiltration concentrate, and separating to obtain fidaxomicin crude product; conducting preparative column chromatography on the fidaxomicin crude product, eluting with an acid aqueous solution containing an organic solvent, and separating to obtain the refined fidaxomicin product.

Abstract: Provided are a Streptomyces (Streptomyces hygroscopicus) HS7523 and a method for preparing milbemycin A3 by culturing the Streptomyces. The Streptomyces (Streptomyces hygroscopicus) HS7523 is deposited in “China General Microbiological Culture Collection Center” with an accession number of CGMCC No. 9672 on Sep. 16, 2014.